文献速递慢性肾脏病水电解质与酸碱

成纤维细胞生长因子23与慢性肾脏病患者尿钠排泄分数相关

Fibroblast growth factor 23 is associated with fractional excretion of sodium in patients with chronic kidney disease.
PubMed 文献 · Nephrol Dial Transplant · 2019-01-01

本研究为横断面研究,纳入180例1-5期非透析慢性肾脏病患者,检测血浆完整FGF23、24小时尿钠排泄、尿钠排泄分数(FENa)及血压。多变量回归分析显示FGF23与FENa独立正相关,在eGFR<60及使用利尿剂者中更强,不支持FGF23导致临床显著钠潴留。

要点

  • 非透析CKD患者中FGF23与FENa独立正相关。
  • 关联在eGFR<60和使用利尿剂者中更强。
  • 数据不支持FGF23引起临床显著钠潴留。

核心结论

  • FGF23与非透析CKD患者FENa升高独立相关,不支持FGF23导致临床显著钠潴留。

研究设计与样本

  • 横断面研究纳入180例1-5期接受肾活检的非透析CKD患者,基线测量血浆完整FGF23、24小时尿钠、FENa和血压。

主要发现

  • 中位年龄52.8岁,男性60.6%,中位eGFR 50.6 mL/min/1.73 m2。
  • 单变量分析FGF23与FENa正相关(Spearman rho=0.47,P<0.001),与收缩压正相关(rho=0.17,P<0.05)。
  • FGF23与FENa的关联在多变量调整后仍显著(β=0.60,P<0.001)。
  • eGFR<60者(n=107)中关联更强(β=0.47,P=0.04),使用利尿剂者(n=73)中β=0.88,P<0.001。
  • 用实测GFR替代eGFR调整不改变关联。

临床怎么用

  • 在非透析CKD患者中解读FGF23水平时,可结合FENa评估钠排泄状态。
  • 对使用利尿剂或eGFR<60者,FGF23与FENa关联更强,需注意利尿剂影响。

局限性

  • 横断面设计无法推断因果关系。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent studies suggest that the phosphaturic hormone fibroblast growth factor 23 (FGF23) is involved in regulation of renal sodium excretion and blood pressure. There is evidence of both direct effects via regulation of the sodium-chloride symporter (NCC) in the distal tubule, and indirect effects through interactions with the renin-angiotensin-aldosterone system. However, clinical data on the association between FGF23 and renal sodium regulation is lacking. Herein, we investigated the associations of FGF23 with renal sodium handling and blood pressure in non-dialysis CKD patients. METHODS: This was a cross-sectional study encompassing 180 CKD patients Stage 1-5, undergoing renal biopsy. Plasma intact FGF23, 24-h urinary sodium excretion, fractional excretion of sodium (FENa) and blood pressure were measured at baseline. The association between FGF23 and renal sodium handling was explored by multivariate regression analysis. RESULTS: The median age was 52.8 years, 60.6% were men and the median estimated glomerular filtration rate (eGFR) was 50.6 mL/min/1.73 m2. In univariate analysis, FGF23 was positively associated with FENa (Spearman's rho = 0.47; P < 0.001) and systolic blood pressure (rho = 0.17, P < 0.05), but not with plasma sodium, 24-h urinary sodium excretion or mean arterial blood pressure. The association between FGF23 and FENa remained significant after adjustment for potential confounders (multivariable adjusted β coefficient 0.60, P < 0.001). This association was stronger among the 107 individuals with eGFR <60 mL/min/1.73 m2 (β = 0.47, P = 0.04) and in the 73 individuals on any diuretics (β = 0.88, P < 0.001). Adjustment for measured GFR instead of eGFR did not alter the relationship. CONCLUSIONS: FGF23 is independently associated with increased FENa in non-dialysis CKD patients. These data do not support the notion that FGF23 causes clinically significant sodium retention. Further studies are warranted to explore the mechanism underlying this association.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Xu H, Hashem A, Witasp A, et al. Fibroblast growth factor 23 is associated with fractional excretion of sodium in patients with chronic kidney disease. Nephrol Dial Transplant. 2019. PMID: 30312430. doi:10.1093/ndt/gfy315

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。